FDA Approves Bepirovirsen: Why Oligonucleotide CDMOs Should Take Note
FDA approves GSK's bepirovirsen for chronic hepatitis B after a 19% functional cure rate, raising oligonucleotide scale-up stakes for manufacturers.
Read the full report on Pharmtech
Story file
How this page works. The Headline Update lists this report from Pharmtech with a short summary and a link to the original. The original reporting and photograph belong to the publisher. Spotted an error in our summary? Tell our corrections desk.
